Botanix Pharmaceuticals Ltd has released a press release.
FDA Qualified Infectious Disease Product Status for BTX 1801
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- Notification regarding unquoted securities - BOT
- Canine Atopic Dermatitis Program Launched
- Final Report and Annual Report to Shareholders
- New Canine Pilot Study Supports Further AD Investigation
- Botanix Update on BTX 1801 Clinical Development
Later from Botanix Pharmaceuticals
- Appendix 4C - Quarterly
- Dermatology Asset Acquired to Accelerate Path to Revenue
- NDA Filing Accelerated and Trials Fully Enrolled
- Application for quotation of securities - BOT
- Change of Director's Interest Notice * 3
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals